Embryotoxic effects of DA-125, a new anthracycline anticancer agent, in rats

새로운 안트라사이클린계 항암제 DA-125의 랫트에 있어서 태자독성효과

  • Chung, Moon-koo (Toxciology Research Center, Korea Research Institute of Chemical Technology) ;
  • Kim, Jong-choon (Toxciology Research Center, Korea Research Institute of Chemical Technology)
  • 정문구 (한국화학연구소 안전성연구부) ;
  • 김종춘 (한국화학연구소 안전성연구부)
  • Received : 1993.12.17
  • Published : 1994.01.31


DA-125 is a new anthracycline antitumor antibiotic, which is derived from adriamycin. The potential of DA-125 to induce embryotoxicity was evaluated in the Sprague-Dawley rats. One hundred twenty naturally mated SD rats(sperm in vaginal lavage=day 0) were distributed among three treated groups and a control group. DA-125 was administered intravenously at dose levels of 0. 0.1, 0.3 and 1.0mg/ kg/day. Dams were treated from day 7 to 17 of gestation and were subjected to the caesarean section on day 20. At 1 mg/kg, reduced food intake, reduced body weight and decreased weight of spleen were observed in dams. An increase in the resorption rate and a reduction in the fetal weight were also found. In addition, various types of external, visceral and skeletal malformations occurred at an incidence of 11.9, 41.8 and 14.5%, respectively. Characteristic malformations include exencephalia, gastroschisis, cleft lip, dilatation of lateral and 3rd ventricle, fused ribs, among others. There were no signs of maternal toxicity or embryotoxicity at 0.1 and 0.3mg/kg. The results show that the test agent DA-125 is embryotoxic at maternally subtoxic dose in rats.